EphB3 protein is a potential ancillary diagnostic biomarker for thyroid cancers

IF 1.5 4区医学 Q3 PATHOLOGY Annals of Diagnostic Pathology Pub Date : 2023-12-25 DOI:10.1016/j.anndiagpath.2023.152262

Xinyue Gao , Rusong Zhang , Yan He , Xuan Wang , Wei Bao , Xiao Feng , Jiaxin Chai , Jiandong Wang

{"title":"EphB3 protein is a potential ancillary diagnostic biomarker for thyroid cancers","authors":"Xinyue Gao , Rusong Zhang , Yan He , Xuan Wang , Wei Bao , Xiao Feng , Jiaxin Chai , Jiandong Wang","doi":"10.1016/j.anndiagpath.2023.152262","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><p>To investigate the expression of ephrin<span> type B receptor 3 (EphB3) in thyroid<span> tumors and its usage as an ancillary diagnostic biomarker for thyroid tumors.</span></span></p></div><div><h3>Methods</h3><p>Formalin-fixed and paraffin-embedded (FFPE) tissue samples (78 cases) and FNAC<span> samples (57 cases) were assessed with the EphB3 antibody using immunohistochemistry<span><span>. PTC and other thyroid follicular tumors were compared regarding their EphB3 expression. </span>Sanger sequencing was used to assess for the presence of a BRAF V600E mutation.</span></span></p></div><div><h3>Results</h3><p><span>EphB3 was positive in 81.8 % (27/33) of papillary thyroid carcinoma (PTC), 83.3 % (5/6) of medullary thyroid carcinoma<span> (MTC), 25 % (1/4) of hyperplastic/adenomatoid nodule (HN), 14.3 % (1/7) of follicular adenoma (FA), and negative in follicular tumors of uncertain malignant potential (FT-UMP) (0/13), noninvasive follicular neoplasm with papillary-like nuclear features (NIFTP) (0/7), </span></span>thyroid follicular carcinoma<span> (TFC) (0/4), Hashimoto's thyroiditis<span> (0/4), and normal thyroid follicular tissues (0/33). In cellular blocks, EphB3 was positive in 87.1 % (20/23) of PTC, 75 % (3/4) of MTC, 20 % (2/10) of HN, and negative in atypia of undetermined significance/follicular lesion of undetermined significance (AUS/FLUS) (0/20) and normal thyroid follicular cells (0/10).</span></span></p></div><div><h3>Conclusion</h3><p>EphB3 is expressed in the majority of PTC, but less so in benign follicular nodules. EphB3 expression in fine needle aspiration cytology (FNAC) specimens can be used as a diagnostic tool to differentiate thyroid cancer from other follicular lesions in its differential diagnosis, especially AUS/FLUS and PTC.</p></div>","PeriodicalId":50768,"journal":{"name":"Annals of Diagnostic Pathology","volume":null,"pages":null},"PeriodicalIF":1.5000,"publicationDate":"2023-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Diagnostic Pathology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1092913423001600","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PATHOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective

To investigate the expression of ephrin type B receptor 3 (EphB3) in thyroid tumors and its usage as an ancillary diagnostic biomarker for thyroid tumors.

Methods

Formalin-fixed and paraffin-embedded (FFPE) tissue samples (78 cases) and FNAC samples (57 cases) were assessed with the EphB3 antibody using immunohistochemistry. PTC and other thyroid follicular tumors were compared regarding their EphB3 expression. Sanger sequencing was used to assess for the presence of a BRAF V600E mutation.

Results

EphB3 was positive in 81.8 % (27/33) of papillary thyroid carcinoma (PTC), 83.3 % (5/6) of medullary thyroid carcinoma (MTC), 25 % (1/4) of hyperplastic/adenomatoid nodule (HN), 14.3 % (1/7) of follicular adenoma (FA), and negative in follicular tumors of uncertain malignant potential (FT-UMP) (0/13), noninvasive follicular neoplasm with papillary-like nuclear features (NIFTP) (0/7), thyroid follicular carcinoma (TFC) (0/4), Hashimoto's thyroiditis (0/4), and normal thyroid follicular tissues (0/33). In cellular blocks, EphB3 was positive in 87.1 % (20/23) of PTC, 75 % (3/4) of MTC, 20 % (2/10) of HN, and negative in atypia of undetermined significance/follicular lesion of undetermined significance (AUS/FLUS) (0/20) and normal thyroid follicular cells (0/10).

Conclusion

EphB3 is expressed in the majority of PTC, but less so in benign follicular nodules. EphB3 expression in fine needle aspiration cytology (FNAC) specimens can be used as a diagnostic tool to differentiate thyroid cancer from other follicular lesions in its differential diagnosis, especially AUS/FLUS and PTC.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

EphB3 蛋白是一种潜在的甲状腺癌辅助诊断生物标记物。

目的研究甲状腺肿瘤中ephrin B型受体3（EphB3）的表达及其作为甲状腺肿瘤辅助诊断生物标志物的应用：方法：使用EphB3抗体对福尔马林固定和石蜡包埋（FFPE）组织样本（78例）和FNAC样本（57例）进行免疫组化评估。比较了 PTC 和其他甲状腺滤泡性肿瘤的 EphB3 表达情况。桑格测序用于评估是否存在BRAF V600E突变：结果：81.8%（27/33）的甲状腺乳头状癌（PTC）、83.3%（5/6）的甲状腺髓样癌（MTC）、25%（1/4）的甲状腺增生/腺瘤样结节（HN）、14.3%（1/7）的甲状腺滤泡性肿瘤（MTC）、25%（1/4）的甲状腺增生/腺瘤样结节（HN）和14.3%（1/7）的甲状腺滤泡性肿瘤（MTC）EphB3均呈阳性。在恶性程度不确定的滤泡性肿瘤（FT-UMP）（0/13）、具有乳头状核特征的非侵袭性滤泡性肿瘤（NIFTP）（0/7）、甲状腺滤泡癌（TFC）（0/4）、桥本氏甲状腺炎（0/4）和正常甲状腺滤泡组织（0/33）中呈阴性。在细胞块中，EphB3在87.1%（20/23）的PTC、75%（3/4）的MTC和20%（2/10）的HN中呈阳性，而在意义未定的不典型性/意义未定的滤泡性病变（AUS/FLUS）（0/20）和正常甲状腺滤泡细胞（0/10）中呈阴性：结论：EphB3在大多数PTC中都有表达，但在良性滤泡结节中表达较少。细针穿刺细胞学（FNAC）标本中的EphB3表达可作为一种诊断工具，用于鉴别诊断甲状腺癌和其他滤泡性病变，尤其是AUS/FLUS和PTC。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Annals of Diagnostic Pathology 医学-病理学

CiteScore

3.90

自引率

5.00%

发文量

149

审稿时长

26 days

期刊介绍： A peer-reviewed journal devoted to the publication of articles dealing with traditional morphologic studies using standard diagnostic techniques and stressing clinicopathological correlations and scientific observation of relevance to the daily practice of pathology. Special features include pathologic-radiologic correlations and pathologic-cytologic correlations.